bispecific antibodies

News

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petose

News

J&J reels in bispecific specialist Proteologix in $850m deal

Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc

News

FDA turns down Regeneron bispecific blood cancer antibody

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL).

News

DISCO dances out of the shadows with €20m for ‘surfaceome’

Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its

News

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending.